Botulinum Toxin for Refractory Trigeminal Neuralgia: A Trial Sequential Analysis of Randomized Clinical Trials.
0/5 보강
APA
Sridharan K, Sivaramakrishnan G (2018). Botulinum Toxin for Refractory Trigeminal Neuralgia: A Trial Sequential Analysis of Randomized Clinical Trials.. Journal of neurosciences in rural practice, 9(1), 3-4. https://doi.org/10.4103/jnrp.jnrp_447_17
MLA
Sridharan K, et al.. "Botulinum Toxin for Refractory Trigeminal Neuralgia: A Trial Sequential Analysis of Randomized Clinical Trials.." Journal of neurosciences in rural practice, vol. 9, no. 1, 2018, pp. 3-4.
PMID
29456335 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 |
함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
같은 제1저자의 인용 많은 논문 (2)
- Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.
- Interventions for Refractory Trigeminal Neuralgia: A Bayesian Mixed Treatment Comparison Network Meta-Analysis of Randomized Controlled Clinical Trials.
📖 전문 본문 읽기 PMC JATS · ~3 KB · 영문 · 색칠된 단어 1개
In this issue, Caldera et al.[1] published a study where the authors observed a significant reduction in the symptoms of trigeminal neuralgia (TN) following injection of botulinum toxin at the trigger point in a cohort of South Asian patients. In our earlier network meta-analysis of interventions for refractory TN, we also observed that botulinum toxin injection was associated with significant benefits compared to placebo.[2] A previous systematic review assessing the prospective studies on botulinum toxin in TN observed therapeutic response ranging between 70% and 100% without any significant major adverse events.[3] Although botulinum toxin is approved only for treating chronic migraine, the analgesic effects of botulinum toxin in TN have already been reported first in 1998. Since then, numerous nonrandomized and observational studies and four randomized controlled clinical trials[4567] have been conducted with botulinum toxin in refractory TN. We carried out a trial sequential analysis[8] assessing the efficacy of botulinum toxin from the estimates of three randomized clinical trials[456] with the methodology described similarly elsewhere.[7] Relative risk (95% confidence intervals) of patients with pain relief was the outcome variable, and one study[7] did not report this outcome. We observed statistically significant pooled estimates (2.86 [1.82, 4.48]) favoring botulinum toxin [Figure 1], and the trial sequential analysis confirmed the existence of adequate evidence for therapeutic utility of botulinum toxin. Although there is no expert consensus on using botulinum toxin in refractory TN due to lack of robust and long-term follow-up studies and cost-effectiveness data, the agent looks promising to use based on trial sequential analysis principles.
출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
- Mechanisms of Botulinum Toxin Type A Action on Pain.
- Effect of Botulinum Toxin Injection on EMG Activity and Bite Force in Masticatory Muscle Disorder: A Randomized Clinical Trial.
- Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.
- Immunogenicity of botulinum toxin.
- Botulinum Toxin in the Treatment of Headache.